JP2025505696A - 生産物の精製方法 - Google Patents

生産物の精製方法 Download PDF

Info

Publication number
JP2025505696A
JP2025505696A JP2024547315A JP2024547315A JP2025505696A JP 2025505696 A JP2025505696 A JP 2025505696A JP 2024547315 A JP2024547315 A JP 2024547315A JP 2024547315 A JP2024547315 A JP 2024547315A JP 2025505696 A JP2025505696 A JP 2025505696A
Authority
JP
Japan
Prior art keywords
protein
antibody
affinity chromatography
interest
eluate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505696A5 (cg-RX-API-DMAC7.html
Inventor
セバスチャン ツルブリッゲン,アンドレアス
イン-アルボン,キャロル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kodiak Sciences Inc
Original Assignee
Kodiak Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kodiak Sciences Inc filed Critical Kodiak Sciences Inc
Publication of JP2025505696A publication Critical patent/JP2025505696A/ja
Publication of JP2025505696A5 publication Critical patent/JP2025505696A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024547315A 2022-02-10 2023-02-09 生産物の精製方法 Pending JP2025505696A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263267810P 2022-02-10 2022-02-10
US63/267,810 2022-02-10
PCT/US2023/062322 WO2023154822A2 (en) 2022-02-10 2023-02-09 Methods of purifying a product

Publications (2)

Publication Number Publication Date
JP2025505696A true JP2025505696A (ja) 2025-02-28
JP2025505696A5 JP2025505696A5 (cg-RX-API-DMAC7.html) 2026-02-12

Family

ID=87521638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547315A Pending JP2025505696A (ja) 2022-02-10 2023-02-09 生産物の精製方法

Country Status (10)

Country Link
US (1) US20230250133A1 (cg-RX-API-DMAC7.html)
EP (1) EP4476237A2 (cg-RX-API-DMAC7.html)
JP (1) JP2025505696A (cg-RX-API-DMAC7.html)
KR (1) KR20240142564A (cg-RX-API-DMAC7.html)
CN (1) CN119032099A (cg-RX-API-DMAC7.html)
AU (1) AU2023217074A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251000A1 (cg-RX-API-DMAC7.html)
IL (1) IL314472A (cg-RX-API-DMAC7.html)
MX (1) MX2024009755A (cg-RX-API-DMAC7.html)
WO (1) WO2023154822A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2021377336A1 (en) * 2020-11-16 2023-07-06 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins
EP4788450A1 (en) * 2023-10-04 2026-08-12 Sartorius BIA Separations d.o.o. Enhanced chromatographic separations of components in a mixture by employing chaotropic elution
WO2025184423A1 (en) * 2024-02-29 2025-09-04 Kodiak Sciences Inc. Cell-surface-targeting-domain-polymer-payload conjugate
US20260070966A1 (en) * 2024-09-06 2026-03-12 Eyebiotech Limited Multivalent fzd4, wnt co-receptor, and vegf receptor molecules and uses thereof
US20260092125A1 (en) * 2024-09-06 2026-04-02 Eyebiotech Limited Multivalent fzd4, wnt co-receptor, and vegf binding molecules and uses thereof
WO2026075981A1 (en) * 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Methods of analyzing heterodimeric proteins
CN119454939A (zh) * 2024-11-28 2025-02-18 北海康成(苏州)生物制药有限公司 一种欧莫扑拜单抗原液及其制备方法
CN119524125A (zh) * 2024-11-28 2025-02-28 北海康成(苏州)生物制药有限公司 一种欧莫扑拜单抗原液的生产方法及欧莫扑拜单抗原液

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045314B2 (en) * 2000-04-04 2006-05-16 Baxter International Inc. Method for the production of bacterial toxins
CN102395597A (zh) * 2009-03-11 2012-03-28 惠氏有限责任公司 纯化小模块免疫药物蛋白的方法
CA2853358A1 (en) * 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
WO2015101586A1 (en) * 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
CN110981957B (zh) * 2014-01-15 2024-12-24 豪夫迈·罗氏有限公司 具有改善的蛋白A结合作用的Fc区变体
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
JP6959912B2 (ja) * 2015-09-23 2021-11-05 ジェネンテック, インコーポレイテッド 抗vegf抗体の最適化変異体
IL290457B2 (en) * 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CA3092588A1 (en) * 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
US20210254073A1 (en) * 2020-02-04 2021-08-19 Cornell University Methods for capture and analysis of macromolecular complexes

Also Published As

Publication number Publication date
AU2023217074A1 (en) 2024-08-15
IL314472A (en) 2024-09-01
EP4476237A2 (en) 2024-12-18
MX2024009755A (es) 2024-08-20
CN119032099A (zh) 2024-11-26
WO2023154822A3 (en) 2023-09-21
WO2023154822A8 (en) 2024-04-04
WO2023154822A2 (en) 2023-08-17
KR20240142564A (ko) 2024-09-30
CA3251000A1 (en) 2023-08-17
US20230250133A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
JP7414371B2 (ja) 抗体および抗体複合体
US20230250133A1 (en) Methods of purifying a product
US20240084043A1 (en) Methods of treating an eye disorder
AU2015279560B2 (en) Dual PDGF/VEGF antagonists
EP4649959A2 (en) Methods of treating an eye disorder
WO2024254281A9 (en) Compositions of conjugated and unconjugated proteins
WO2024254282A2 (en) Methods for analyzing mixed compositions of protein and protein conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260203